Welcome to our dedicated page for Horizon Therapeutics Plc news (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Plc stock.
Horizon Therapeutics plc (NASDAQ: HZNP) is a global biotechnology company dedicated to the discovery, development, and commercialization of medicines for rare, autoimmune, and severe inflammatory diseases. Horizon’s mission is to blend science and compassion to transform the lives of patients who are often underserved. The company’s therapeutic portfolio includes innovative products such as TEPEZZA® (teprotumumab-trbw) and KRYSTEXXA® (pegloticase injection), which address critical medical needs.
Horizon is driven by a deep understanding of the patient journey and aims to bring clinically meaningful therapies to those who need them most. The company is heavily invested in scientific research and development, and this commitment is evident in its robust pipeline of medicines designed to address complex medical conditions.
Recently, Horizon entered into a consent order agreement with the Federal Trade Commission (FTC) to resolve a pending administrative lawsuit, clearing the way for its acquisition by Amgen (NASDAQ: AMGN). This deal is expected to close in early fourth-quarter 2023, pending final approvals. Amgen, a pioneer in biotechnology, is committed to advancing human therapeutics and has been recognized as one of “America’s Greatest Workplaces” by Newsweek and one of “America’s Climate Leaders” by USA Today.
Horizon’s commitment to combining scientific expertise with compassionate care sets it apart in the biotech industry. By focusing on areas of high unmet medical need, Horizon aims to deliver breakthrough therapies that can improve health outcomes and dramatically enhance the quality of life for patients around the world.
For more information on Horizon and its groundbreaking work, visit its official website at HorizonTherapeutics.com and follow the company on social media platforms such as Twitter, LinkedIn, Instagram, and Facebook.
Horizon Therapeutics plc (NASDAQ: HZNP) has released a Rule 8.1 dealing disclosure under the Irish Takeover Panel Act. The disclosure pertains to Timothy P. Walbert, a person acting in concert with the offeree (as a director of Horizon Therapeutics). On June 1, 2023, Walbert purchased 279 ordinary shares at a price of $76.07 per unit.
Following this transaction, Walbert owns or controls 3,737,295 ordinary shares, representing 1.633% of the company's relevant securities. The disclosure also corrects a previous error in the January 6, 2023 Rule 8.1 Disclosure, which incorrectly stated Walbert's ownership as 3,620,605 shares. The correct number of shares owned on January 5, 2023, was 3,737,016.
FAQ
What is Horizon Therapeutics?
What products does Horizon Therapeutics offer?
What recent achievements has Horizon Therapeutics made?
Who is acquiring Horizon Therapeutics?
How is Horizon Therapeutics contributing to medical science?
What is the mission of Horizon Therapeutics?
How can I learn more about Horizon Therapeutics?
What is the significance of Horizon’s recent agreement with the FTC?
Where is Horizon Therapeutics headquartered?
What is the focus of Horizon's research and development efforts?
